论文部分内容阅读
Objective To investigate the clinical effects and safety of bevacizumab combined with S-1 as thesecond-line treatment of recurrent and/or metastatic esophageal cancer after chemoradiation.Methods Patients with recurrent or metastatic esophageal cancer aft